News

Global biopharma Bristol-Myers Squibb has joined the public-private Angola Sickle Cell Initiative to provide Angolan children who have sickle cell disease with an effective therapy unavailable to many patients in the West African country. The initiative is a collaborative project of the Angola Ministry of Health, the…

Researchers investigated the use of hydroxyurea, a drug approved to treat sickle cell anemia in adults, in young children in New York State who are receiving this treatment. The findings reveal that pediatric use of hydroxyurea is widespread and increasing, but that incomplete adherence may limit the treatment’s full disease-modifying effects. The study,…

Global Blood Therapeutics, a biopharma developing novel therapeutics for the treatment of blood-based disorders, recently announced new results from its ongoing Phase 1/2 study of GBT440-001 in sickle cell disease (SCD). The data, presented at the European Hematology Association’s 21st Congress in Copenhagen, further supports the company’s plans to develop GBT440 as a…

With interest growing in the potential of community health workers to aid in the management and care of people with sickle cell disease (SCD), researchers investigated the possibilities, making suggestions for how best to use, train and evaluate these workers. Researchers recently investigated and summarized the potential of community health workers…

June 19 was World Sickle Cell Awareness Day, but while more than 94% of children with the disease in the United States live happier, full lives because of early diagnoses and good healthcare; the survival rate of children with sickle cell disease in sub-Saharan Africa sits at an alarming 10%. Knowing that 225,000 children in…